BRIEF published on 06/12/2024 at 06:35, 1 year 5 months ago Siegfried to Acquire Early-Phase CDMO in Wisconsin to Boost Drug Substances Offering Acquisition CDMO Growth Opportunities Pharmaceutical Drug Development
BRIEF published on 06/12/2024 at 06:35, 1 year 5 months ago Siegfried va acquérir CDMO en phase précoce dans le Wisconsin pour renforcer son offre de substances médicamenteuses Acquisition CDMO Opportunités De Croissance Pharmaceutique Développement De Médicaments
PRESS RELEASE published on 06/12/2024 at 06:30, 1 year 5 months ago Siegfried to acquire an early-phase CDMO in Wisconsin (US) to strengthen its Drug Substances service offering Siegfried AG acquires early-phase CDMO in Wisconsin to enhance Drug Substances service offering, aiming for growth and expanded capabilities in North America Acquisition CDMO Wisconsin Siegfried AG Drug Substances
Published on 12/05/2025 at 02:35, 5 hours 33 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 7 hours 8 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 9 hours 3 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 9 hours 8 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 1 hour 8 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 4 hours 38 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 8 hours 17 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 43 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 53 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 53 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 14 hours 8 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 14 hours 8 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 14 hours 23 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 14 hours 23 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
